# Global Health Investment Corporation

> Global Health Investment Corporation is a VC fund backing Health Care. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 15
- Last investment: Mar 2026
- Lead investor: 27%
- Last updated: Aug 2026
- Website: https://ghicfunds.org

Global Health Investment Corporation is a VC fund focused on Health Care and Biotechnology. Global Health Investment Corporation ccelerates the development of technologies that improve human health around the world.

## Contacts

5 contacts available for Global Health Investment Corporation. Shizune tracks 1 team members at Global Health Investment Corporation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/global-health-investment-corporation-f967?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 47% |
| Biotechnology | 6 | 40% |
| Medical | 3 | 20% |
| Manufacturing | 2 | 13% |
| Machine Learning | 2 | 13% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 20% |
| Series D | 3 | 20% |
| Series A | 2 | 13% |
| Venture - Series Unknown | 2 | 13% |
| Seed | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 47% |
| Belgium | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Labeeb Abboud | Chairman and CEO | 1 | https://shizune.co/investors/profile/labeeb-abboud |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $50M | Series C | Mar 26, 2026 |  |
| Prenosis | Prenosis Inc. is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its ImmunixTM precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data to more holistically capture and illuminate the complex healthstates of patients. Its proprietary NOSISTM dataset is the largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The Sepsis ImmunoScoreTM diagnostic on the ImmunixTM platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually. | $20M | Series A | Jan 29, 2026 |  |
| Antheia | Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $24M | Series C | Jan 27, 2026 |  |
| Antheia | Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $56M | Series C | Jun 03, 2025 |  |
| Micron Biomedical | Micron Biomedical is a clinical-stage biopharmaceutical company on a rapid path to bring drugs and vaccines to market. The company was founded in 2014 and is based in Atlanta, Georgia. | $16M | Series A | Jan 16, 2025 |  |
| CytoVale | Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California, United States. | $100M | Series D | Oct 10, 2024 |  |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $12M | Venture - Series Unknown | May 22, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Venture - Series Unknown | Apr 04, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Series D | Apr 04, 2024 |  |
| CytoVale | Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California, United States. | $84M | Series C | Nov 15, 2023 |  |

10 of 15 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 3 deals together
- [Alpha Wave Ventures](https://shizune.co/investors/profile/alpha-wave-ventures) — VC Fund, 2 deals together
- [Aphelion Capital](https://shizune.co/investors/profile/aphelion-capital) — VC Fund, 2 deals together
- [ATHOS KG](https://shizune.co/investors/profile/athos-kg) — VC Fund, 2 deals together
- [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Global Health Investment Corporation invest in?

Global Health Investment Corporation invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series D stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Global Health Investment Corporation?

Public channels for Global Health Investment Corporation include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Global Health Investment Corporation?

The team at Global Health Investment Corporation includes Labeeb Abboud (Chairman and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co